Is it safe for a patient taking lenvatinib (Lenvima) and pembrolizumab (Keytruda) with a normal complete blood count to undergo dental cleaning and scaling?

Dental Cleaning and Scaling is Generally Safe with Normal CBC

Yes, dental cleaning and scaling can proceed safely in a patient on lenvatinib (Lenvima) and pembrolizumab (Keytruda) with a normal complete blood count, though heightened bleeding precautions are essential.

Key Considerations

Bleeding Risk Assessment

The primary concern with this combination therapy is hemorrhagic events. Both lenvatinib and pembrolizumab carry bleeding risks, and their combination may amplify this concern 1, 2, 3. However, with a normal CBC (particularly normal platelet count and hemoglobin), the patient's baseline hematologic parameters support proceeding with routine dental procedures.

• Lenvatinib alone causes hemorrhagic events in 27% of patients (any grade), with serious bleeding in approximately 5% 1
• The combination shows hemorrhagic adverse events, though real-world data suggests the risk is manageable with appropriate precautions 3
• A normal CBC indicates adequate platelet function and clotting capacity for minor dental procedures

Stomatitis/Oral Mucositis Considerations

Stomatitis is a common adverse effect of this combination therapy:

• Occurs in 43% of patients receiving lenvatinib-pembrolizumab (Grade 3-4 in 2%) 1
• May complicate healing after dental procedures
• Assess current oral mucosal integrity before proceeding

Procedural Recommendations

For routine dental cleaning and scaling:

1. Proceed with standard infection control practices 4

   • Sterile instruments for all procedures involving soft tissue contact
   • Proper barrier techniques and protective equipment
   • Standard handwashing protocols

2. Implement enhanced hemostatic measures:

   • Use local hemostatic agents readily available
   • Apply direct pressure to bleeding sites
   • Consider hemostatic mouthwash post-procedure
   • Avoid aggressive subgingival scaling if possible

3. Timing considerations:

   • Ideally schedule between treatment cycles when drug levels may be lower
   • Avoid scheduling immediately after infusion/dosing

4. Monitor for delayed complications:

   • Instruct patient on signs of excessive bleeding
   • Provide clear instructions for managing post-procedure bleeding
   • Ensure patient has access to emergency dental care

When to Defer or Modify

Consider postponing if:

• Active oral mucositis/stomatitis is present (wait for healing)
• Patient reports recent bleeding episodes
• Hypertension is uncontrolled (common with lenvatinib: 56% incidence) 1
• Recent dose escalation or treatment initiation (<2 weeks)

Communication with Oncology Team

While not absolutely required for routine cleaning with normal labs, consider notifying the oncology team if:

• More invasive periodontal procedures are planned
• Patient has had recent bleeding complications
• Multiple extractions or surgical procedures are contemplated

Clinical Pitfalls to Avoid

• Do not assume normal CBC eliminates all bleeding risk - the drugs affect vascular integrity beyond platelet count
• Do not perform deep scaling without adequate hemostatic preparation - have materials ready before starting
• Do not ignore active stomatitis - this increases infection risk and impairs healing
• Do not proceed if hypertension is severely uncontrolled - this amplifies bleeding risk

The evidence supports that routine dental procedures can be performed safely with appropriate precautions in patients on this combination therapy when hematologic parameters are normal 4, 5. The key is preparation for potential bleeding and assessment of oral mucosal integrity.